Astria Therapeutics Inc. (ATXS), which shared positive initial proof-of-concept results from its ALPHA-STAR trial in March, has a couple of noteworthy developments on the horizon.
ALPHA-STAR is a phase Ib/II proof-of-concept trial assessing single and multiple doses of the company's drug candidate STAR-0215 in patients with Hereditary Angioedema (HAE) types I and II.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com